{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:50:59Z","timestamp":1790884259595,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Background. Patients with \u03b2-thalassemia have a high incidence of atrial fibrillation (AF) and other supraventricular arrhythmias. The use of non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prophylaxis in patients with \u03b2-thalassemia has not been systematically evaluated. Methods. We enrolled patients with transfusion-dependent \u03b2-thalassemia, who were on treatment with NOACs for thromboembolic prophylaxis of supraventricular arrhythmias. Data on thromboembolic and bleeding events were collected. Results. Eighteen patients were enrolled. The patients had a history of AF (sixteen), typical atrial flutter (five), and atypical atrial flutter (four). The patients were treated with dabigatran (seven), apixaban (five), rivaroxaban (four) or edoxaban (two). The mean follow-up duration was 22 \u00b1 15 months. No thromboembolic events were reported. No major bleedings were observed. Three patients had non-major bleeding events. Two patients reported dyspepsia during treatment with dabigatran and were shifted to a different NOAC. Conclusions. Our study suggests the efficacy and safety of NOACs in patients affected by transfusion-dependent \u03b2-thalassemia.<\/jats:p>","DOI":"10.3390\/biology12040491","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T03:16:46Z","timestamp":1679627806000},"page":"491","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-Vitamin K Antagonist Oral Anticoagulants in Patients with \u03b2-Thalassemia"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1972-9665","authenticated-orcid":false,"given":"Michele","family":"Malag\u00f9","sequence":"first","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-0382","authenticated-orcid":false,"given":"Filomena","family":"Longo","sequence":"additional","affiliation":[{"name":"Day Hospital Thalassemia and Hemoglobinopathies, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-4881","authenticated-orcid":false,"given":"Federico","family":"Marchini","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sirugo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Capanni","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4169-2977","authenticated-orcid":false,"given":"Stefano","family":"Cl\u00f2","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mari","sequence":"additional","affiliation":[{"name":"Day Hospital Thalassemia and Hemoglobinopathies, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2718-2404","authenticated-orcid":false,"given":"Martina","family":"Culcasi","sequence":"additional","affiliation":[{"name":"Day Hospital Thalassemia and Hemoglobinopathies, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5285-7140","authenticated-orcid":false,"given":"Matteo","family":"Bertini","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra2021838","article-title":"\u03b2-Thalassemias","volume":"384","author":"Taher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/ejh.13512","article-title":"Changing patterns in the epidemiology of \u03b2-thalassemia","volume":"105","author":"Kattamis","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","article-title":"Beta-thalassemia","volume":"12","author":"Cao","year":"2010","journal-title":"Genet. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Schiroli, D., Merolle, L., Quartieri, E., Chicchi, R., Fasano, T., De Luca, T., Molinari, G., Pulcini, S., Pertinhez, T.A., and Di Bartolomeo, E. (2021). Comparison of two alternative procedures to obtain packed red blood cells for \u03b2-thalassemia major transfusion therapy. Biomolecules, 11.","DOI":"10.3390\/biom11111638"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0140-6736(22)00536-0","article-title":"Thalassaemia","volume":"399","author":"Kattamis","year":"2022","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Malag\u00f9, M., Marchini, F., Fiorio, A., Sirugo, P., Cl\u00f2, S., Mari, E., Gamberini, M.R., Rapezzi, C., and Bertini, M. (2022). Atrial Fibrillation in \u03b2-Thalassemia: Overview of Mechanism, Significance and Clinical Management. Biology, 11.","DOI":"10.3390\/biology11010148"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/thalassrep13010005","article-title":"Cardiovascular Complications in \u03b2-Thalassemia: Getting to the Heart of It","volume":"13","author":"Akiki","year":"2023","journal-title":"Thalass. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/03630269.2018.1488724","article-title":"Atrial fibrillation in \u03b2-thalassemia Major Patients: Diagnosis, Management and Therapeutic Options","volume":"42","author":"Barbero","year":"2018","journal-title":"Hemoglobin"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/anec.12389","article-title":"Electrocardiographic Presentation, Cardiac Arrhythmias, and Their Management in \u03b2-Thalassemia Major Patients","volume":"21","author":"Russo","year":"2016","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1253\/circj.CJ-12-1036","article-title":"Stroke and thromboembolism in atrial fibrillation","volume":"76","author":"Pisters","year":"2012","journal-title":"Circ. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1160\/TH06-05-0267","article-title":"Prevalence of thromboembolic events among 8860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran","volume":"96","author":"Taher","year":"2006","journal-title":"Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.20938","article-title":"Cerebrovascular accident in beta-thalassemia major (beta-TM) and beta-thalassemia intermedia (beta-TI)","volume":"83","author":"Karimi","year":"2008","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100912","DOI":"10.1016\/j.cpcardiol.2021.100912","article-title":"Thrombotic Events and Anticoagulants in Beta-thalassemia Patients with Focus on Anticoagulants for Atrial Fibrillation: A Brief Review","volume":"47","author":"Bahrani","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/03630269.2017.1374969","article-title":"Rivaroxaban Use in Patients with Hemoglobinopathies","volume":"41","author":"Apostolou","year":"2017","journal-title":"Hemoglobin"},{"key":"ref_22","first-page":"477","article-title":"Heavy metal! A case of severe iron overload and supraventricular arrhythmias in a thalassemia major patient","volume":"23","author":"Marchini","year":"2022","journal-title":"G. Ital. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajh.21117","article-title":"Stroke in thalassemia: A dilemma","volume":"83","author":"Taher","year":"2008","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIR.0b013e31829b2be6","article-title":"Cardiovascular Function and Treatment in \u03b2-Thalassemia Major","volume":"128","author":"Pennell","year":"2013","journal-title":"Circulation"},{"key":"ref_28","first-page":"116","article-title":"Oxidative stress and age-related changes in T cells: Is thalassemia a model of accelerated immune system aging?","volume":"41","author":"Esmaeili","year":"2016","journal-title":"Cent. J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood.2022017594","article-title":"Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in \u03b2-thalassemia: Role of an additional dose","volume":"140","author":"Carsetti","year":"2022","journal-title":"Blood"},{"key":"ref_30","unstructured":"FDA, and CDER (2022, November 19). Highlights of Prescribing Information, Available online: www.fda.gov\/medwatch."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/03630269.2019.1689997","article-title":"Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism: A Prospective Cohort Study of 12 Patients","volume":"43","author":"Christen","year":"2019","journal-title":"Hemoglobin"}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/12\/4\/491\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:01:44Z","timestamp":1760122904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/12\/4\/491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["biology12040491"],"URL":"https:\/\/doi.org\/10.3390\/biology12040491","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}